Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Jun Ho Bae 6 Articles
The usefulness of newly developed R2CHA2DS2-VASc score and comparison with CHADS2 and CHA2DS2-VASc scores in atrial fibrillation patients.
Jae Hoon Kwak, Se Hwan Yeo, Yeo Un Kim, Jin Suk Lee, Byong Kyu Kim, Jin Wook Chung, Jun Ho Bae, Deuk Young Nah, Kwan Lee
Yeungnam Univ J Med. 2016;33(1):8-12.   Published online June 30, 2016
DOI: https://doi.org/10.12701/yujm.2016.33.1.8
  • 2,240 View
  • 18 Download
AbstractAbstract PDF
BACKGROUND
The decision to administer oral anticoagulation therapy depends on accurate assessment of stroke risk in patients with atrial fibrillation (AF). Various stroke risk stratification schemes have been developed to help inform clinical decision making. The CHADS2 and CHA2DS2-VASc scores have been used in estimating the risk of stroke in patients with AF. Recently R2CHA2DS2-VASc score was developed. The objective of the current study is to validate the usefulness of the R2CHA2DS2-VASc score and to compare the accuracy of the CHADS2, CHA2DS2-VASc, and R2CHA2DS2-VASc scores in predicting a patient's risk of stroke. METHODS: Based on medical records, we conducted a retrospective study of patients hospitalized with AF from March 2011 to July 2013. A total of 448 AF patients were included in this study. The receiver operating characteristic (ROC) curve analysis in MedCalc was used for comparison with respective diagnostic values. RESULTS: The patient characteristics showed male predominance (60.9%). Among the 448 AF patients, 131 (29.2%) patients had strokes during the study. A R2CHA2DS2-VASc score of more than 5 is the optimal cut-off value for prediction of stroke. A risk score of three, the area under the ROC curve (AUC) of R2CHA2DS2-VASc score (AUC 0.631; 95% confidence interval, 0.585-0.679) was the highest. A significant difference was observed between AUC for R2CHA2DS2-VASc, CHADS2, and CHA2DS2-VASc scores, but no meaningful difference between CHADS2 and CHA2DS2-VASc scores. CONCLUSION: We determined the usefulness of the R2CHA2DS2-VASc score, which showed better association with stroke than the CHADS2 and CHA2DS2-VASc scores.
Treatment of pulmonary thromboembolism using Arrow-Trerotola percutaneous thrombolytic device.
Tae Kyun Kim, Ji Young Park, Jun Ho Bae, Jae Woong Choi, Sung Kee Ryu, Min Jung Kim, Jun Bong Kim, Jang Won Sohn
Yeungnam Univ J Med. 2014;31(1):28-32.   Published online June 30, 2014
DOI: https://doi.org/10.12701/yujm.2014.31.1.28
  • 2,050 View
  • 7 Download
  • 1 Crossref
AbstractAbstract PDF
Pulmonary thromboembolism (PTE) increases the pressure of the right ventricle and leads to symptoms and signs, such as dyspnea and hypoxia. If PTE causes hemodynamic instability, thrombolytic therapy should be considered. A mechanical thrombectomy is an alternative treatment to thrombolytic therapy and should be considered when thrombolytic therapy is contraindicated. Various devices are used in mechanical maceration and catheter-directed thrombolysis, but there is no standard mechanical device for PTE as yet. We report here on 2 clinical experiences of mechanical thrombectomy using the Arrow-Trerotola percutaneous thrombolytic device to remove residual clots after systemic thrombolysis in patients with massive PTE.

Citations

Citations to this article as recorded by  
  • Pulmonary thromboembolism combined with intracardiac thrombus occurred during the steroid reduction in nephrotic syndrome patient
    Se Jin Lee, Ji Young Park, Sung Kee Ryu, Jae Woong Choi, Won Young Chae, Hee Yun Ryu, Min Seok Yoo, Yoon Suk Bak
    Yeungnam University Journal of Medicine.2016; 33(1): 25.     CrossRef
Treatment of Coronary Artery Perforation and Tamponade Complicating Balloon Angioplasty by PTFE-Covered Stent. A Case Report.
Jong Seon Park, Gu Ru Hong, Jun Ho Bae, Ihn Ho Cho, Bong Sup Shim, Young Jo Kim, Dong Gu Shin
Yeungnam Univ J Med. 2005;22(1):90-95.   Published online June 30, 2005
DOI: https://doi.org/10.12701/yujm.2005.22.1.90
  • 1,336 View
  • 5 Download
AbstractAbstract PDF
A coronary artery perforation is a rare but often fatal complication of angioplasty. We experienced a coronary artery perforation and cardiac tamponade during balloon angioplasty. A polytetrafluorethylene (PTFE) -covered stent was used to successfully close the perforation.
Primary Cardiac Lymphoma: Case Report.
Jun Ho Bae, Jong Suk Lee, Hyung Jun Kim, Min Kyung Kim, Young Ho Park, Gue Ru Hong, Jong Sun Park, Dong Gu Sin, Young Jo Kim, Bong Sup Sim
Yeungnam Univ J Med. 2000;17(1):82-86.   Published online June 30, 2000
DOI: https://doi.org/10.12701/yujm.2000.17.1.82
  • 1,767 View
  • 3 Download
AbstractAbstract PDF
Primary cardiac lymphoma defined as involving only the heart and pericardium, is very rare and is diagnosed predominantly late in the course of illness or autopsy. This tumor is commonly fatal and until recently were rarely diagnosed antemortem. Recently, it was reported in patients with acquired immunodeficiency syndrome. We report a case of primary cardiac lymphoma in a 56 year old female who showed progressive exertional dyspnea. On echocardiogram and CT scan, large ill defined mass was demonstrated in right atrial and ventricular wall. It was diagnosed as B-cell type lymphoma on open cardiac biopsy.
The Effect of Early IABP and Reperfusion therapy in Patient of Post MI Cardiogenic shock.
Jong Suk Lee, Min Kyeung Kim, Woong Kim, Hyung Jun Kim, Jun Ho Bae, Jong Seon Park, Dong Gu Sin, Young Jo Kim, Bong Sup Shim
Yeungnam Univ J Med. 2000;17(1):31-38.   Published online June 30, 2000
DOI: https://doi.org/10.12701/yujm.2000.17.1.31
  • 1,492 View
  • 1 Download
AbstractAbstract PDF
BACKGROUND
We sought to examine the use and outcomes with early intraaortic balloon couterpulsation(IABP) combined early reperfusion therapy in patients presenting with cardiogenic shock complicating acute myocardial infarction. The use of IABP in patients with cardiogenic shock is widely accepted. however, there is a paucity of information on the use of this technique in patients with cardiogenic shock who are treated with reperfusion therapy in Korea. MATERIALS AND METHODS: Twenty-eight Patients presented with cardiogenic shock were classified into two groups: the early IABP group (insertion within 12 hours after AMI onset time) and late IABP group (insertion after 12 hours). We compared In-hospital mortality in two group (early IABP group vs late IABP group). RESULTS: Two groups show no significant difference at clinical feature and coronary angiographic results. Among total 28 patients, 7 patients were treated with thrombolytic therapy and 21 patients with PTCA. Insertion site bleeding, fever, thrombocytopenia were reported as some of the complications of IABP insertion. In-hospital mortality of early IABP group and late IABP group were 4 patients(25%) and 8 patients(66%), respectively(p<0.05). Early IABP insertion and early PTCA showed lower hospital mortality rates. There was significant difference in the time to PTCA after AMI onset between the to groups(p<0.05). CONCLUSION: IABP appears to be useful in patients presenting with cardiogenic shock unresponsive medical therapy. Early IABP insertion and early Reperfusion therapy may reduce In-hospital mortality rates in PostMI Cardiogenic shock patients.
Antihypertensive effect and safety of imidapril on the patient with essential hypertension.
Gue Ru Hong, Jun Ho Bae, Dae Jin Jun, Jong Seon Park, Dong Gu Shin, Young Jo Kim, Bong Sup Sim
Yeungnam Univ J Med. 1999;16(1):69-75.   Published online June 30, 1999
DOI: https://doi.org/10.12701/yujm.1999.16.1.69
  • 1,655 View
  • 3 Download
AbstractAbstract PDF
Imidapril(Tanatril(R)), a newly developed ACE inhibitor, has been used to treat hypertension and congestive heart failure. This study was designed to assess the antihypertensive effect and safety of Imidapril(Tanatril(R)) in patient with essential hypertension. 5-10mg of imidapril(Tanatril(R)) was administered once day in 30 patients with essential hypertension and followed up to 8 weeks. We tested the drug's effectiveness, safety, and the incidence of imidapril induced dry coughs. After 8 weeks of treatment with Imidapril, 76.2%(16/21) of patient showed lowered blood pressure and 47.6% showed normal blood pressure. The overall incidence of adverse effects was 33.3%(7/21). and among these adverse effects. dry cough was shown in only 9.5%. Thus, concluded that imidapril(Tanatril(R)) is as safe and effective as other ACE inhibitors. especially with imidapril showing very little incidence of dry cough compared to other ACE inhibitors.

JYMS : Journal of Yeungnam Medical Science